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Abstract: Heterogeneity, frequent diagnostic fluctuation across presentations, and global concerns 
with the absence of effective treatments all encourage science that moves the field toward individualized or 
precision medicine in eating disorders. We review recent advances in psychiatric genetics focusing on genome-
wide association studies (GWAS) in eating disorders. Given that the only eating disorder to be the subject of 
GWAS to date is anorexia nervosa, we review anorexia GWAS and enumerate the prospects and challenges of a 
genomics-driven approach towards personalized intervention in eating disorders. 
Keywords: eating disorders, genetics, GWAS, heterogeneity, anorexia nervosa, polygenic risk score, heritability, pathways. 
1. INTRODUCTION 
 Clinicians’ options for the treatment of eating disorders —
especially anorexia nervosa—remain meager at best. To date, 
only two medications (approved by the US Food and Drug 
Administration) are available that significantly improve the 
core symptoms of eating disorders in the short term 
(fluoxetine for bulimia nervosa [BN] [1], lisdexamfetamine 
for binge-eating disorder [BED] [2,3]). Evidence-based 
psychological interventions remain the recommended first-
line approach to eating disorder treatment [4]. However, a 
subset of patients do not opt for psychological interventions, 
and those who do, in many parts of the world, do not receive 
evidence-based treatments [5]. The recent Diagnostic and 
Statistical Manual (DSM-5) [6] reclassification of feeding and 
eating disorders increased the number of young people 
meeting diagnostic criteria for eating disorders [7] and may 
also have increased heterogeneity both within and between 
diagnoses [8]. Recognition of the phenotypic and etiological 
variability within psychiatry has promoted a call for a 
precision medicine approach in the field [9–11], which may 
prove beneficial for eating disorders. Understanding the 
genetics of eating disorders has emerged as an important early 
first step in the quest for a precision medicine approach [9]. 
However, caution is warranted, as premature conclusions can 
cloud rather than clarify. We discuss the current state of 
genetics in eating disorders, focusing on genome-wide studies 
of DNA variation and their future role in precision medicine 
for eating disorders. Table 1 presents a broad overview of 
genetic methodologies previously used in eating disorders and 
current status. 
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2. GENETICS OF EATING DISORDERS 
Early family studies and large twin-based studies of eating 
disorders formed the foundation of the genetics of eating 
disorders. Heritability estimates from twin studies continue to 
be one of the most consistently replicated findings within 
eating disorder pathogenesis [12]. Average heritability 
estimates across anorexia nervosa (AN), bulimia nervosa 
(BN), and binge-eating disorder (BED) range from 40% to 
65% [13]. Limited research on the genetics of newly 
introduced purging disorder (PD) indicate familial effects, but 
replication is required [14,15]. Very little research exists on 
the heritability of night eating syndrome (NES), but the few 
studies indicate moderate heritability [16]. To date, no studies 
on the genetics of avoidant-restrictive food intake disorder 
(ARFID), pica and rumination disorder have been completed.  
Initial linkage and candidate gene studies yielded 
inconsistent and ultimately unfruitful findings. 
Retrospectively, given the genetic architecture of psychiatric 
disorders, the linkage- and candidate-based approaches were 
unlikely to crack the genetic code to eating disorders. 
Linkage-based studies require costly large family pedigrees 
and candidate gene-based studies required much larger 
sample sizes and effect sizes than we ever imagined [17]. 
Moreover, in the absence of sound information about the 
underlying biology of the illnesses, candidate gene 
approaches rested on guess work regarding which genes might 
be operative. This is an unlikely goal as current estimates 
suggest that hundreds, if not thousands of genes will 
contribute to complex psychiatric phenotypes such as eating 
disorders [12,13,18,19]. In contrast, large-scale genome-wide 
association studies (GWAS) have historically provided much
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Table 1. Overview of genetic methodologies used in eating disorder research to identify genetic variants to 
date. 
Methodologies Type Aim Status 
Quantitative 
Genetics  
Family studies Determine whether traits or disorders 
aggregate in families. 
AN, BN, BED, PD runs 
in families. 
Twin & 
adoption studies 
Estimate the influence and relative 
contribution of genetic and environmental 
factors on human traits. Distinguish between 
shared and nonshared environmental factors. 
Generate estimates of heritability.  
Consistently demonstrate 
heritability and 
significant contribution 
of nonshared 
environmental factors in 
AN, BN, and BED. 
Molecular 
Genetics  
Linkage studies Identifies genomic regions that have an 
increased likelihood of containing genes that 
are associated with a disorder or trait. 
Conducted on samples of related individuals 
(i.e., affected relative pairs, dense pedigrees) 
and does not require a priori hypotheses based 
on biological function or prior data. 
Inconsistent results and 
few replications. 
Candidate gene 
association 
studies 
Comparing frequencies of different alleles of 
one or several genetic markers between cases 
and healthy controls in a hypothesis-driven 
manner.  
Inconsistent results, none 
specific to eating 
disorders, and few 
replications. 
Genome-wide 
association 
studies (GWAS) 
Investigate the genetics of psychiatric 
disorders using information from and 
coverage of the whole genome in a 
hypothesis-neutral manner. GWAS focuses 
on common genetic variation. Can provide 
SNP-based heritability estimates. 
Large sample sizes are 
necessary; first locus 
identified via GWAS for 
AN; samples needed for 
other eating disorders.  
 
more robust results within psychiatry [19]. To date, only 
genome-wide studies in AN have been completed; thus, we 
focus our review on studies on AN. In AN, we recently 
identified the first genome-wide significant locus on 
chromosome 12 using association techniques in eating 
disorders [20]. 
Given the recent GWAS findings in eating disorders, we 
discuss basic concepts related to the genetic architecture of 
complex psychiatric disorders and the interpretation of 
GWAS results. We then review recent findings of common 
and rare genetic variation from genome-wide studies in eating 
disorders, including studies of whole-genome association, 
analysis of copy number variants (CNVs), and exome 
sequencing to identify rare transmitted and de novo variation. 
We also discuss infrastructure necessary for genetic 
advancement of precision medicine for eating disorders. Last, 
in order to transition from bench to bedside, we consider 1) 
the promise of these genetic findings; 2) effective ways to 
discuss novel findings with patients and families, and use of 
genetic counselors; and 3) reconceptualization of the 
disorders that may lead to novel ideas for treatment.  
3. GENETIC ARCHITECTURE OF EATING 
DISORDERS 
 As with most psychiatric disorders, eating disorders have 
a complex etiology involving genetic, environmental, and 
population-level liability. Evidence suggests that a large 
number—probably hundreds to thousands—of genes 
contribute to the disorder, yet each gene is only responsible 
for a slight increase in risk [12,21,22]. Thus, eating disorders 
do not appear to follow the traditional Mendelian pattern of 
inheritance, but rather their genetic contribution is polygenic. 
This complex genetic architecture and poor understanding of 
their neurobiology has stymied linkage and candidate gene 
studies of eating disorders. The effect sizes of the possible 
genes involved in eating disorders are too small to be detected 
using linkage or candidate gene study designs [13,18,23,24], 
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whereas their utility in the study of diseases with single gene 
Mendelian patterns of inheritance, such as Huntington’s 
disease is high. Linkage studies rely on rare genetic variation 
(genetic risk variants that have a large effect). To detect 
common genetic variation, we have turned to genome-wide 
studies. Advances in the genetic epidemiology of eating 
disorders have recently been reviewed (see [12]) and are 
outside the scope of this review. 
4. INTERPRETING GENETIC VARIATION FROM 
GENOME-WIDE STUDIES  
 As humans, we share a large section of our genome and 
hence a substantial amount of genetic variation [25]. GWAS 
are designed to identify these common genetic variants 
(present in more than 1% of the genome) that individually 
confer a small increased risk of illness but that added together 
may account for a substantial fraction of the heritability of a 
particular condition. Since 2005, GWAS has become a staple 
in human genetics research, with 2940 published studies 
curated in the National Human Genome Research Institute 
(NHGRI)–European Bioinformatics Institute (EBI) catalog of 
published GWAS (the GWAS Catalog) [26–28] as of May 
2017. Likewise, over 36,066 SNPs have been identified that 
are associated with one or more trait(s).  
 Identification of risk variants and loci via GWAS indicates 
that a genetic region is associated with disease status. 
However, the identification of risk loci via GWAS does not 
necessarily mean that the actual susceptibility of genes at 
these loci have been confidently identified. Genotypes at 
neighboring DNA variants often correlate within a population, 
known as linkage disequilibrium (described in detail in 
section 6.1), and association signals can span large genomic 
regions with more than one gene. Identifying the underlying 
causal variants and their biological effect is a considerable 
challenge.   
5. COMMON GENETIC VARIATION FROM 
GENOME-WIDE STUDIES IN EATING DISORDERS 
 Microarray technology has provided a powerful tool for 
studying the genetic contribution of eating disorders and 
allows for the measurement of gene expression levels 
genome-wide. We review a number of recent studies using 
genome-wide association approaches to identify genes or 
pathways of genes in AN. 
5.1. Whole-Genome Association Studies 
 The first GWAS for AN was conducted by the Children’s 
Hospital of Philadelphia (CHOP) and the Price Foundation 
Collaborative Group [29]. Given the small sample size (1,033 
AN cases; 3,733 pediatric controls) and genetic architecture 
of psychiatric disorders (see above), no SNPs reached 
genome-wide significance (p≤5x10-8). Also complicating the 
design was the fact that the control group had not yet passed 
through the age of risk for developing AN (M = 12.75 years; 
SD = 4.2 years) and so were effectively unscreened for eating 
disorders and other genetically related psychiatric problems, 
resulting in decreased statistical power to detect association.  
The second AN GWAS was performed by the Genetic 
Consortium for Anorexia Nervosa (GCAN) as part of the 
Wellcome Trust Case-Control Consortium 3 (WTCCC3). 
This GWAS included 2,907 AN cases of European ancestry 
and 14,860 ancestry-matched female controls. Although this 
was a larger study, it is still a modest sample size for GWAS 
and no genome-wide significant loci were detected, although 
when 72 independent markers with the lowest p values were 
selected for replication, sign tests revealed that a highly 
significant 76% of these markers yielded results in the same 
direction in the discovery and the replication sample [30]. 
These tests encouraged the field to continue GWAS efforts as 
it suggested that the significant signal did exist in the data, but 
larger samples were required for detection. The controls 
selected for this GWAS were also not ideal. Although they 
were selected to be ancestrally compatible, they had been 
genotyped on similar (but not identical) platforms and at 
different times and in different laboratories. 
 In an effort to unite research groups and consolidate 
findings, the Eating Disorders Working Group of the 
Psychiatric Genomics Consortium (PGC-ED) was established 
in 2013. The first analysis of the combined CHOP and 
WTCCC3 datasets emerged in 2016, and has reported the first 
genome-wide significant locus for AN in an area that harbors 
genes previously implicated in type 1 diabetes and other 
autoimmune disorders on chromosome 12 [20]. The GWAS 
comprised 3,495 cases and 10,982 controls and now has been 
imputed to Phase 3 of 1000 Genomes Project to enable 
association statistics at millions of un-genotyped variants to 
be calculated [25].  
 There is no question that GWAS has rapidly accelerated 
scientific advancement in the field of psychiatric genetics 
[31], yet, limitations of the method should also be 
acknowledged. First, psychiatric diagnoses made from formal 
diagnostic criteria, such as the DSM-5 [6] or the International 
Classification of Diseases (ICD-10) [32], are based on 
symptom clusters derived from clinical and empirical 
observations. Psychiatric nosology does not necessarily 
reflect genetics, biology, or neuroscience. Biomarkers of 
illness in psychiatry are lacking. Approaches such as the 
Research Domain Criteria (RDoc) attempt to overcome this 
issue via a biologically-informed remodelling of psychiatric 
nosology [33]. GWAS can address this problem by 
investigating clinical subtypes of psychiatric disorders (e.g., 
restricting or binge-purge AN), symptom-based analyses 
(e.g., symptom scores derived from questionnaires), or 
presumed endophenotypes (e.g., brain structures). 
Unfortunately, much larger sample sizes are required with 
these approaches.  
 Second, significant hits, or ‘loci’, identified through 
GWAS mark regions of the genome, but do not directly 
identify the genes themselves nor their causal alleles. The 
associated loci often are non-coding or harbour several genes, 
complicating the identification of a causal variant contributing 
to disorder risk. Furthermore, the effect sizes of the 
association between these loci and the disorder are small and 
mostly do not exceed odds ratios of 1.2. Given that these are 
complex traits, influenced by hundreds and possibly 
thousands of genes, small effect sizes are to be expected [34]. 
However, genetic variation acting in an additive manner is 
only one piece of the total genetic puzzle. Many genetic 
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mechanisms act in concert, such as common and rare genetic 
variation, gene-environment interactions mediated by 
epigenetic factors including DNA methylation, histone 
modification and non-coding RNAs, and hormonal factors, 
which directly bind DNA motifs and may change gene 
expression. Ultimately, the contribution of all of these factors 
needs to be investigated by a systems biology approach [35]. 
GWAS, thus, does not represent an end-point, but rather a 
stepping-stone for subsequent complex analyses and novel 
pathway discovery.  
6. NEW TECHNIQUES FOR CAPTURING 
POLYGENICITY OF EATING DISORDERS 
 Polygenicity is the aggregate effect of genetic variants 
(possibly thousands) within a disease. Polygenicity is often 
too small to be picked up in GWAS, but contributes to disease 
liability [36]. It is believed that environmental factors (i.e., 
internalization of the societal thin ideal in eating disorders) 
contributes, but it is unknown how this plays out in each 
individual. New techniques to capture polygenicity are rapidly 
being developed.  
6.1. Linkage disequilibrium score regression  
 A pattern of linkage disequilibrium (LD) across the whole 
genome is exploited to derive heritabilities and genetic 
correlations. If two genes are in linkage disequilibrium, it 
means that certain genomic regions are inherited together 
more often than would be expected by chance (e.g., genes that 
located close to each other on the same chromosome). The 
genetic overlap between two disorders or traits is referred to 
as the genetic correlation. SNPs contribute in two ways to a 
phenotype. The SNP on its own has a partial contribution to 
the phenotype, but also all variants which are in LD with that 
index SNP contribute to the phenotype. SNPs in chromosomal 
loci of high LD therefore are more likely to be in LD with a 
variant that may have a true effect on the phenotype. SNPs in 
this chromosomal loci of high LD may on average contribute 
more to the phenotype. A variety of methods to analyze 
genome-wide studies have been developed from LD-score 
regression. Genome-wide studies using LD-score regression 
methods in eating disorders are reviewed below. 
6.2. Genome-wide SNP-based heritability and partitioned 
heritability 
 Heritability refers to the proportion of phenotypic variance 
in a population attributable to additive genetic factors [37]. 
Twin based heritabilities in eating disorders are estimated 
between 40% to 65%. GWAS results can also be used to 
calculate so-called SNP-based heritabilities which describe 
the total phenotypic variance explained by common genetic 
variants using LD-score regression [38]. The SNP-based 
heritability for AN derived from the most recent GWAS is 
estimated to be 20% meaning that 20% of the liability to 
develop AN is attributable to common genetic variants. 
Furthermore, it is possible to divide this heritability by cell-
type groups, yielding partitioned heritability [39]. Partitioned 
heritability analysis tests the contribution of each cell-type 
group to the SNP-based heritability. The sample size of the 
current GWAS on AN was too small and therefore 
underpowered to estimate significant partitioned heritabilities.  
6.3. Genetic correlations 
 Two traits or disorders can share genetic variants which 
contribute to their genetic liability. If a genetic variant 
contributes to more than one trait this variant is assumed to be 
pleiotropic. The degree of shared genetic contribution is 
approximated by genetic correlations. Genetic correlations 
can be estimated by an analytical extension of LD-score 
regression. AN shows a broad range of genetic correlations 
which can be split into major sub-categories: personality, 
psychiatry, education, anthropometry, glucose, and lipid 
metabolism. AN exhibited positive genetic correlations with 
neuroticism, schizophrenia, educational attainment, and lipid 
measures [20]. These correlations suggest shared genetics 
between those traits.  
 The positive genetic correlation with neuroticism—a 
personality trait associated with anxiety and major 
depression—may partly explain the comorbidity between AN 
and mood disorders. A positive genetic correlation reflects the 
same genes influencing both target traits in the same direction. 
Thus, a genetic variant that increases one’s liability to score 
high on a neuroticism scale also may increase one’s chance of 
developing AN. Genetic correlations are dependent on the 
SNP-based heritability of both traits. Higher SNP-based 
heritabilities decrease the corresponding standard error of a 
genetic correlation, indicating the precision of a heritability 
estimate. Conversely, a higher standard error indicates a lower 
precision of the heritability estimate. Varying measures of 
neuroticism yield SNP-based heritabilities between 3%-8% 
[40,41] resulting in genetic correlations of 0.39 (SE=14) and 
0.28 (SE=0.06) with AN [20]. 
 Whereas, the genetic overlap with schizophrenia may 
implicate a psychotic component to the disorder which may 
express itself in the disturbed body image observed in clinical 
samples. The positive genetic correlation with years of 
education and attending college may reflect the increased 
perfectionism which is observed in AN. 
 Surprisingly, high-density lipoproteins showed a positive 
genetic correlation with AN. They are widely recognized as a 
positive marker of cardiovascular health. Measures of an 
unfavorable glucose metabolism such as insulin resistance, β-
cell function, and fasting insulin, as well as glucose were 
negatively genetically correlated with AN suggesting that AN 
may represent a status of increased insulin sensitivity with 
reduced insulin production. Furthermore, negative genetic 
correlations with measures of body adiposity were observed, 
suggesting that the same genetic variants may influence 
extremes of body adiposity in both directions [20]. This 
pattern of genetic correlations encourages a 
reconceptualization AN as an illness that contains both 
psychiatric and metabolic components. Post-GWAS 
investigations are needed to explore mechanisms of metabolic 
action that may contribute to the perplexing catastrophic and 
often precipitous weight loss in susceptible individuals. To 
extend the findings of GWAS, the exploration of disorder-
associated genomic regions is important by, for instance, fine 
mapping or exome sequencing to identify causal variants in 
genes. Moreover, investigations, such as large-scale 
proteomics and lipidomics could be applied to deeply 
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phenotype patients suffering from any kind of eating disorder. 
These methods can identify altered levels of metabolites on a 
systems biology level and help us to understand the severe 
weight and appetite dysregulation observed in eating 
disorders, especially in AN. 
6.4. Polygenic risk scores.  
 Single SNP analysis do not fully capture the polygenic 
architecture of psychiatric disorders. Polygenic risk scores 
(PRS), however, can be used to incorporate several SNPs, 
which are associated most strongly with an eating disorder, 
into an overall composite score. Software like PLINK, 
PRSice, or GCTA can be used for these computations [42–
44]. These composite scores have three main applications: 
within-trait association, cross-trait association, and prediction. 
First, we can determine if genome-wide identified polygenic 
risk scores are associated with the same trait in a second 
cohort (i.e., within-trait association, external validation of the 
phenotype). The typical procedure to derive polygenic risk 
scores consists of a discovery sample and a target sample. The 
polygenic risk score is calculated in the discovery sample and 
then used to predict cases in the target sample. Second, 
polygenic risk scores can be applied to assess the genetic 
overlap between disorders and traits (cross-trait association). 
A polygenic risk score can be used to replicate genetic 
correlations between traits (i.e., educational attainment) and 
phenotypes (i.e., AN) which were calculated by LD-score 
regression. In the case of educational attainment and AN, a 
higher polygenic risk score for educational attainment should 
also predict case status in AN. Last, if a temporal aspect is 
added to the prediction models in which polygenic risk scores 
are used, it may be possible in the future to predict disease 
onset, course of the disorder, optimal treatment, and possibly 
treatment response [45]. 
 After investigating the polygenic architecture of eating 
disorders, two questions remain: First, why do all related 
individuals with a similar genetic background develop eating 
disorders? Second, what contributes to individual differences 
in susceptibility to environmental stressors and protective 
factors? Polygenic risk scores can facilitate our understanding 
of gene-environment interplay and address these open 
questions. Progress in this area is limited by the scarcity of 
genotyped and longitudinally phenotyped study populations 
with sufficient numbers of participants [46]. 
 To date, only one study applying polygenic risk scores 
within anorexia nervosa has been completed. The AN 
polygenic risk score was derived from the most recent AN 
GWAS and was used to predict the ability to recognize facial 
emotions, which has been shown to be disrupted in psychiatric 
disorders broadly [47,48] and AN specifically [49,50]. In the 
study the polygenic risk score for AN did not predict the 
ability to recognize facial emotions in others [51]. However, 
the study had several limitations. First, in this sample, facial 
emotion recognition did not yield an estimate for heritability. 
Second, the study population may be too young for the 
phenotype studied as the average age was 8.5 (SD = 1.0) and 
largely pre-pubescent. This is key as facial emotion 
recognition increases after puberty [52]. Third, the phenotype 
measure exhibited modest internal consistency for the 
identification of all faces and even lower internal consistency 
for specific emotions. Finally, the original AN GWAS had a 
low sample size decreasing power of the polygenic risk score 
as such. Further studies using polygenic risk scoring are 
needed to investigate the polygenic architecture of eating 
disorders and its predictive value. 
6.5. Gene-wise analysis and pathway analysis. 
 Systems biology approaches can be applied to the results 
of GWAS to understand the underlying biology of eating 
disorders. It is important to link identified risk loci to 
biological pathways. This linking can help find relevant 
biological processes, cell types and brain circuits involved in 
eating disorders. Two types of analyses are normally 
conducted: gene-wide analysis and pathway analysis using 
software like MAGMA, INRICH, and ALIGATOR [53]. 
GWAS summary statistics are exploited to identify genes or 
whole pathways that are more strongly associated with the 
phenotype compared with all other genes or pathways in a set. 
To date, there are different sets of biological pathways 
depending on which databases are used to generate those 
pathway sets, such as Reactome, GO database, KEGG 
pathway database, and MSigDB [54,55]. Larger sample sizes 
are needed to identify significant genes or pathways 
associated with AN. 
7. RARE GENETIC VARIATION IN GENOME-WIDE 
STUDIES OF EATING DISORDERS 
 In contrast to common genetic variation, rare genetic 
variation is assumed to have larger biological impact on the 
phenotype. Rare genetic variation is defined to occur at a 
frequency lower than 1% in the population. This includes very 
rare or private variants with a frequency below 0.01%, and 
copy number variants (CNVs), which can be inherited or de 
novo (non-inherited).  
7.1. Copy number variation 
 Two genome-wide analyses of CNVs have been 
conducted in AN. There are no other analyses of CNVs 
covering the other eating disorders. In the first, no evidence 
emerged supporting enrichment of AN cases for CNVs above 
controls, and rare or large CNVs were not notably 
overrepresented in AN cases [29]. A novel and recurrent 
13q12 deletion (1.5 Mb) disrupting sacsin molecular 
chaperone (SACS) was seen twice in cases and CNVs 
disrupting the contactin 6/contactin 4 (CNTN6/CNTN4) 
region were found in multiple cases, although the study lacked 
significant sample size to detect rare pathogenic CNVs. In the 
second, a case-only genome-wide CNV survey explored 
whether pathogenic CNVs implicated in other psychiatric and 
neurodevelopmental disorders were also observed in AN 
cases [56]. Four of these well-established pathogenic CNVs 
(deletions or duplications in 1q21.1, 7q36.3, 15q13.3, or 
16p11.2) were found in a small number of AN cases. One case 
also had a large deletion in the 13q12 region [56], and 41 cases 
had deletions or duplications which were 1 Mb or larger. 
However, at this point it is not clear whether large effect 
CNVs play a demonstrable role in AN. Larger sample sizes 
are required to detect the effect of rare CNVs. 
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8. TOWARDS PRECISION PSYCHIATRY IN EATING 
DISORDERS 
 GWAS represent a starting point for genetic discovery 
which may lead to precision psychiatry. In some ways, eating 
disorder treatment has consistently utilized precision 
medicine approaches; providers integrate signs and 
symptoms, scientific evidence, their own training and 
expertise, and patient needs in order to facilitate a treatment 
plan. New models of precision medicine emphasize the use of 
an individual's genetic information and measurable 
biomarkers to optimize treatment [57]. The significance of 
these discoveries lies in their potential ability to identify a 
causal link from gene to cellular and molecular mechanisms 
underlying eating disorder symptoms.  
 The coming year marks thirty years of evidence for the 
genetic basis of eating disorders [58] and as a field, we are just 
at the beginning. Identification of the genetic mechanisms 
underlying AN from genome-wide studies has just begun, yet 
are obsolete all other eating disorder subtypes. The future of 
eating disorder identification and treatment will depend on the 
timely transition of research findings into more effective and 
efficient care. The identification of the underlying polygenic 
architecture of AN, for instance, could enable healthcare 
providers to estimate a genetic liability to develop AN later in 
life. A polygenic liability, however, does not equal a 
deterministic factor. Individuals with a high genetic liability 
can be buffered by an advantageous and beneficial 
environment and possibly never express their genotypic risk, 
but the opposite is also possible. Individuals with a low 
genetic liability may be exposed to disadvantageous and 
precipitating environments, and be exposed to several 
stressors which trigger the development of an eating disorder 
to which they are only minimally genetically susceptible. As 
new findings from the genetics of eating disorders emerge, 
these message of disease liability (rather than disease 
determination) should be translated to patients and families. 
As genetic information about eating disorders reaches the 
general population, patients and families understandably raise 
questions about transmission of eating disorders to the next 
generation. It is often assumed that genetic counselors only 
play a role in transmission of Mendelian inherited diseases; 
however, this is untrue. Genetic counselors play a meaningful 
role in counseling individuals about transmission of disorders 
with complex inheritance patterns such as psychiatric 
illnesses [59]. As such, it is of value to engage genetic 
counselors sooner as these questions are arising clinically with 
increasing frequency. 
 Apart from risk prediction, genomic tools to capture the 
polygenic architecture of eating disorders may allow for 
characterization of new subtypes and resulting tailored 
treatments. For example, genetic risk profiles may 
differentiate between psychiatric, metabolic, or activity-based 
subtypes of AN. These subtypes may be distinguishable by 
their different genetic profiles. Applying the most efficacious 
treatments, or new treatments developed specifically to 
emerging biologically-based subtypes, may maximize our 
ability to target treatments to causes. Additionally, the 
presence of genetic differences or similarities may also 
explain the high diagnostic crossover between eating disorder 
presentations. For example, early detection of risk that 
presages transition from AN to BN, could flag the importance 
of clinicians working toward resolution of AN symptoms 
without precipitating migration to BN. Although this should 
always be the clinical goal, at present our ability to predict 
who will experience diagnostic crossover is limited [60–65]. 
 To reach these aims and best serve our patients, facilitation 
of international collaboration in the eating disorders field is a 
must. We need to conduct GWAS covering all other eating 
disorders, especially BN and BED. GWAS of all eating 
disorders could enable the health care providers to identify not 
only eating disorder trajectories such as diagnostic crossover, 
but also risk for chronicity, adverse somatic outcomes, and 
risk of death. Treatment of eating disorders is challenging for 
providers, for families, and for patients as evidence-based 
treatments are limited and optimal treatment prediction 
models sparse. GWAS datasets encompassing all eating 
disorder phenotypes may assist in choosing the optimal 
treatment to facilitate full recovery and avoid crossover and 
adverse outcomes.  
8. CONCLUSION  
 We are at the very beginning of conceptualizing precision 
medicine initiatives with genomic information. Genomic 
discovery in AN is accelerating rapidly, but work on BN and 
BED is woefully behind. Very large sample sizes (in the tens 
of thousands) are key to discovering genetic variants 
associated with risk, and global cooperation is underway to 
achieve such sample sizes. Advances in genomic methods, 
coupled with increasing knowledge about environmental risk 
factors, will provide a more complete and accurate picture of 
eating disorder etiology and allow us to move rapidly toward 
personalized treatment.  
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